Autres langues Editas Medicine, Inc.

Actions

EDIT

US28106W1036

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
5,32 ^USD	+1,92 %		-3,10 %	-47,48 %

13/03	Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
29/02	EDITAS MEDICINE, INC. : Barclays maintient sa recommandation neutre	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	22/04
Editas Medicine : April 2024 Corporate Presentation	12/04
Editas Medicine : Corporate Effectiveness Report April 2024	12/04
Editas: Q4 Earnings Snapshot	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02
North American Morning Briefing : Stock Futures -2-	21/02
Editas Medicine to Participate in Upcoming Investor Conferences	31/01
Editas Medicine to Participate in Upcoming Investor Conferences	31/01
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	08/01
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	08/01
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update	13/12
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9	13/12
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals	13/12
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	13/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Editas Medicine, Inc.

Actions

EDIT

US28106W1036

Autres langues

Filtres